Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P00505: Variant p.Arg262Gly

Aspartate aminotransferase, mitochondrial
Gene: GOT2
Feedback?
Variant information Variant position: help 262 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glycine (G) at position 262 (R262G, p.Arg262Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In DEE82; decreased glutamate oxaloacetate transferase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 262 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 430 The length of the canonical sequence.
Location on the sequence: help FDMAYQGFASGDGDKDAWAV R HFIEQGINVCLCQSYAKNMG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         FDMAYQGFASGDGDKDAWAVRHFIE--------QGINVCLCQSYAKNMG

Mouse                         FDMAYQGFASGDGDKDAWAVRHFIE--------QGINVCLC

Rat                           FDMAYQGFASGDGDKDAWAVRHFIE--------QGINVCLC

Pig                           FDMAYQGFASGDGNKDAWAVRHFIE--------QGINVCLC

Bovine                        FDMAYQGFASGDGNKDAWAVRHFIE--------QGINVCLC

Rabbit                        FDMAYQGFASGDGDKDAWAVRHFIE--------QGINVCLC

Horse                         FDMAYQGFASGDGNKDAWAVRYFIE--------QGINVCLC

Chicken                       FDMAYQGFASGDINRDAWALRHFIE--------QGIDVVLS

Xenopus tropicalis            FDMAYQGFASGDTNRDAWAVRHFIQ--------EGINVVLS

Zebrafish                     FDMAYQGFASGDIDRDAWAVRYFIE--------QGHNILLS

Slime mold                    FDFAYQGFASGSPEKDAAAVRMFVE--------DGHNIALC

Baker's yeast                 VDMAYQGLESGNLLKDAYLLRLCLNVNKYPNWSNGI--FLC

Fission yeast                 LDMAYQGFASGDFARDAYATRLFAS--------SNVPMLLC
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 30 – 430 Aspartate aminotransferase, mitochondrial
Modified residue 279 – 279 N6-(pyridoxal phosphate)lysine; alternate
Modified residue 279 – 279 N6-acetyllysine; alternate
Helix 259 – 266



Literature citations
Bi-allelic GOT2 mutations cause a treatable malate-aspartate shuttle-related encephalopathy.
van Karnebeek C.D.M.; Ramos R.J.; Wen X.Y.; Tarailo-Graovac M.; Gleeson J.G.; Skrypnyk C.; Brand-Arzamendi K.; Karbassi F.; Issa M.Y.; van der Lee R.; Droegemoeller B.I.; Koster J.; Rousseau J.; Campeau P.M.; Wang Y.; Cao F.; Li M.; Ruiter J.; Ciapaite J.; Kluijtmans L.A.J.; Willemsen M.A.A.P.; Jans J.J.; Ross C.J.; Wintjes L.T.; Rodenburg R.J.; Huigen M.C.D.G.; Jia Z.; Waterham H.R.; Wasserman W.W.; Wanders R.J.A.; Verhoeven-Duif N.M.; Zaki M.S.; Wevers R.A.;
Am. J. Hum. Genet. 105:534-548(2019)
Cited for: FUNCTION; CATALYTIC ACTIVITY; INVOLVEMENT IN DEE82; VARIANTS DEE82 LEU-209 DEL; GLY-262; GLY-337 AND VAL-366; CHARACTERIZATION OF VARIANTS DEE82 GLY-262 AND VAL-366;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.